Genmab — August 2018
-
Overså i første omgang bemærkningen om et bcma-problem. På asco blev der ikke nævnt noget vedr. bb2121. Ganske vist får de fleste pts crs, men i mild grad. Og hvis der er et problem med bcma må det vel være på safety-siden. http://www.cancernetwork.com/asco-multiple-myeloma/bcma-targeting-car-t-cell-tx-effective-rr-mm
-
Ok. Så mangler vi bare en der lige køber for 31-32 millioner kroner

-
Ikke Genmab specifikt, men alligevel dejligt hvis kræften får baghjul for 95% af dem. https://www.dr.dk/nyheder/viden/kroppen/ny-blodproeve-afsloerer-95-procent-af-alle-kraefttyper
-
Dette er egentlig ikke en nyhed, men jeg har først nu set det ekstra studie med ofatumumab i Japan i RMS (Japan var ikke med i de to gange fase 3): https://clinicaltrials.gov/ct2/show/NCT03249714?term=ofatumumab+Relapsing+Multiple+Sclerosis&rank=2
-
God morgen

-
God morgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind